Pulmonary Rehabilitation Nutrition Market

How big is the Pulmonary Rehabilitation Nutrition Market in 2026?

USD 185.4 Million in 2026 and USD 430.9 Million by 2036 at an 8.8% CAGR.

The pulmonary rehabilitation nutrition market stands at USD 185.4 Million in 2026 and is projected to reach USD 430.9 Million by 2036, growing at an 8.8% CAGR. Market demand is fundamentally tied to rehabilitation pathways that treat exercise training and nutrition as deeply linked components of recovery. In 2023, the American Thoracic Society strongly recommended pulmonary rehabilitation for stable COPD, post-COPD hospitalization, and interstitial lung disease. When routine nutrition screening identifies low intake or muscle loss, rehabilitation teams have a highly defined, clinical reason to add medical oral nutrition rather than leaving dietary support outside the core program.[1]

Operating conditions differ significantly by country. U.S. CDC data published in April 2026 revealed that COPD prevalence among adults aged 45 and older was highest in nonmetropolitan areas, drastically increasing the importance of home delivery and remote follow-up. UK and German pathways formalize referral and rehabilitation access much more directly. South Korea presents a different constraint: while reimbursement successfully expanded pulmonary rehabilitation, national evidence found that service delivery remained heavily concentrated in tertiary hospitals. Consequently, revenue depends entirely on active referral and dietetic assessment. Product access and repeat use matter just as much as the underlying disease burden.[2][4][6][10]

Market Size and Forecast

Table 1: Market Size and Forecast for the Pulmonary Rehabilitation Nutrition Market (USD Million), 2025 to 2036

Metric	Value
Estimated Market Size in 2025	USD 170.4 Million
Estimated Market Size in 2026	USD 185.4 Million
Projected Market Size by 2036	USD 430.9 Million
CAGR, 2026 to 2036	8.8%

Key Takeaways

• Pulmonary rehabilitation creates the primary demand pathway because exercise actively raises energy and protein needs at the exact same time that dyspnea, poor appetite, and post-hospital deconditioning severely constrain intake.
• High-Fat Low-CHO Pulmonary ONS leads Product Type with a 40.0% share in 2026 because pulmonary-specific formulations give clinicians a familiar, targeted option when carbon-dioxide production and calorie density are critical considerations.
• COPD leads the Condition segment with a 46.7% share in 2026 because it possesses the deepest rehabilitation evidence base and explicit guideline pathways for both stable disease and post-exacerbation recovery.
• Outpatient Pulmonary Rehab leads Program Setting with a 50.3% share in 2026 because repeated, supervised visits actively support nutrition screening, supplement initiation, and ongoing adjustment alongside progressive exercise.
• The main purchasing friction is clinical heterogeneity. While nutritional supplementation can improve weight or selected outcomes, systematic-review evidence does not support a single, universal formula strategy for every rehabilitation patient.

Profiled companies include Abbott (Pulmocare), Nestle Health Science (Nutren Pulmonary), Danone Nutricia (Respifor), Fresenius Kabi, Meiji Holdings, Medtrition, Victus, and B. Braun.

Analyst Perspective

Demand reliably converts to repeat revenue only when the rehabilitation team can identify a measurable nutrition problem, match the formula to the patient's tolerance and respiratory needs, and maintain use after discharge or between supervised sessions.

- Anurag Sharma, Future Market Insights

How is the pulmonary rehabilitation nutrition market segmented?

The market is segmented by Product Type, Condition, Program Setting, End User and Sales Channel.

Product Type comprises High-Fat Low-CHO Pulmonary ONS, High-Protein Rehab Formulas, Compact Energy-Dense ONS (Dyspnea-Adapted), and Others. Condition covers COPD, Post-Pneumonia & ARDS Recovery, Interstitial Lung Disease, and Others. Program Setting comprises Outpatient Pulmonary Rehab, Inpatient Rehab, and Home-Based Programs. End User includes Rehab Centers, Homecare, Hospitals, and Others. Sales Channel comprises Hospital Pharmacy, Retail Pharmacy, Online, Institutional Tender, and Others.

Why do High-Fat Low-CHO Pulmonary ONS lead the Product Type category?

High-Fat Low-CHO Pulmonary ONS hold 40.0% of Product Type in 2026.

Pulmonary-specific high-fat, lower-carbohydrate formulas address a respiratory concern that is entirely distinct from general high-calorie supplementation: carbohydrate oxidation generates significantly more carbon dioxide per unit of oxygen consumed than fat oxidation. While this doesn't make the format universally superior, it provides clinicians with a highly targeted option for selected patients with limited ventilatory reserve. Abbott and Nestle Health Science both document pulmonary formulas built specifically around this metabolic profile, which sustains strong category recognition within respiratory care. High-Fat Low-CHO Pulmonary ONS holds 40.0% of Product Type revenue in 2026.[12][13][14]

• High-Fat Low-CHO Pulmonary ONS account for 40.0% of Product Type in 2026.
• Targeted Metabolic Rationale: The segment's leadership is driven by the physiological need to reduce carbon dioxide production in patients with severe respiratory compromise, making lower-carbohydrate, higher-fat profiles a targeted option for selected patients.[12][13][14]
• Established Clinical Familiarity: Decades of use and foundational clinical trials (such as a landmark 2003 study showing favorable respiratory-function changes in low-body-weight COPD patients) have cemented these specific formulations as a standard, recognizable option for respiratory dietitians.[12]

What keeps COPD at the center of the Condition category?

COPD holds 46.7% of Condition in 2026.

COPD uniquely combines high rehabilitation eligibility with frequent, severe nutritional risk. Breathlessness can drastically reduce meal size, while systemic disease and rigorous exercise rehabilitation simultaneously increase the need to preserve body mass and muscle function. The clinical pathway is also unusually explicit. The American Thoracic Society guideline covers both stable and post-hospitalization COPD, while NICE embeds diet advice and nutritional assessment directly within COPD rehabilitation protocols. This combination gives respiratory nutrition a much clearer prescribing context than less standardized recovery pathways. COPD holds 46.7% of Condition revenue in 2026.[1][4]

• COPD accounts for 46.7% of Condition in 2026.
• Explicit Guideline Pathways: The segment dominates because NICE guidance includes diet advice and nutritional assessment within COPD rehabilitation, transforming dietary intervention from an optional add-on into a standard of care.[4]
• Recurring Need for Muscle Preservation: The systemic nature of COPD, combined with the physical demands of rehab, creates a continuous, measurable need to manage weight loss, muscle depletion, and inadequate intake throughout the functional recovery process.

Why is Outpatient Pulmonary Rehab the leading Program Setting?

Outpatient Pulmonary Rehab holds 50.3% of Program Setting in 2026.

Outpatient programs create highly valuable, repeated decision points. Clinicians can closely observe exercise tolerance and weight trajectory over several weeks, allowing them to monitor appetite and adherence in real time rather than relying on a single, static discharge recommendation. This environment perfectly supports the trial-and-adjust use of oral supplements. The setting also perfectly fits patients who are medically stable enough for structured rehabilitation but still require supervised progression. While home programs improve geographic reach and inpatient rehab remains vital after severe illness, outpatient care retains the broadest intersection between active clinical oversight and repeat consumption. Outpatient Pulmonary Rehab represents 50.3% of Program Setting revenue in 2026.[1][4][5]

• Outpatient Pulmonary Rehab accounts for 50.3% of Program Setting in 2026.
• Continuous Monitoring and Adjustment: The leading position is driven by the ability of outpatient teams to continuously monitor a patient's tolerance, appetite, and functional progress, allowing them to dynamically adjust nutritional prescriptions over multi-week programs.
• Bridge Between Acute Care and Home: Outpatient settings capture patients who are stable enough to leave the hospital but still require the multidisciplinary supervision necessary to properly initiate and validate specialized medical nutrition.

Why do Rehab Centers lead the End User category?

Rehab Centers hold 47.0% of End User in 2026.

Rehab Centers serve as the exact point where nutrition can be seamlessly integrated with exercise progression, rather than being managed as an isolated retail decision. Multidisciplinary teams can actively identify low BMI, recent weight loss, swallowing difficulties, poor appetite, or exercise-related fatigue. They can then immediately route the patient to a dietitian or prescribe a medical nutrition product while actively monitoring tolerance. Hospitals remain critical around acute exacerbations, and homecare becomes vital after transition, but the rehabilitation center is where specification and follow-up are most naturally connected. Rehab Centers hold 47.0% of End User revenue in 2026.[4][5]

• Rehab Centers account for 47.0% of End User in 2026.
• Multidisciplinary Care Integration: Rehab centers dominate because they house the dietitians, respiratory therapists, and physicians necessary to comprehensively assess a patient's nutritional deficits and prescribe targeted formulas within the context of their physical therapy.
• Institutional Infrastructure: As highlighted by national analyses in markets like South Korea, the expansion of pulmonary rehab relies heavily on the institutional infrastructure of hospitals and specialized centers to coordinate this complex, multidisciplinary care.[10]

Why does Hospital Pharmacy lead the Sales Channel category?

Hospital Pharmacy holds 50.2% of Sales Channel in 2026.

Hospital Pharmacy benefits heavily from the strict clinical status of many products in this market. Foods for special medical purposes and medical oral nutrition are typically introduced following a formal physician or dietitian assessment. Initiation is especially relevant around acute exacerbations or the start of structured rehabilitation. Hospital formulary access drastically reduces uncertainty over product suitability and creates a vital bridge into post-discharge purchasing. While retail and online channels matter once a patient is established on a product, and institutional tenders drive bulk purchasing, the hospital pharmacy remains the primary gateway for clinical initiation. Hospital Pharmacy accounts for 50.2% of Sales Channel revenue in 2026.[13][14][15][16][20]

• Hospital Pharmacy accounts for 50.2% of Sales Channel in 2026.
• Gatekeepers of Clinical Initiation: The channel leads because specialized pulmonary formulas require professional assessment and medical supervision, making the hospital pharmacy the natural and most trusted point of entry for new patients.[13][14][15][16]
• Formulary Oversight and Discharge Planning: Hospital pharmacies ensure that the selected product aligns with medical supervision and formulary standards, actively facilitating the transition from inpatient initiation to post-discharge home use.

What are the drivers, restraints and opportunities in the pulmonary rehabilitation nutrition market?

Demand rises as pulmonary rehabilitation becomes embedded in chronic respiratory care, while variable response and access constrain routine supplementation, and compact high-protein formats create an opening for better adherence across outpatient and home programs.

• Driver: Formal pulmonary rehabilitation pathways create recurring, structured points for nutrition screening and medical ONS initiation.
• Restraint: Heterogeneous trial results and individual patient tolerance make routine, one-size-fits-all formula selection much more difficult than the guideline referral to rehabilitation itself.
• Opportunity: Compact, protein-dense, and home-compatible formats can extend vital nutrition support beyond supervised sessions without increasing the physical burden of eating for dyspneic patients.

The central driver is the ongoing normalization of pulmonary rehabilitation as standard chronic respiratory care. ATS recommendations actively cover stable COPD, post-hospitalization COPD, interstitial lung disease, and telerehabilitation. Similarly, NICE describes nutrition as a core component of multidisciplinary COPD rehabilitation. These pathways turn malnutrition risk from a general wellness concern into a heavily monitored clinical issue. For suppliers, the demand mechanism is strongest when dietitians and rehabilitation teams actively screen for weight change or low intake during a program, creating a clear specification point for pulmonary-specific ONS, high-protein supplements, or compact energy-dense formats.[1][4]

The main restraint is evidence heterogeneity. A 2020 systematic review of 22 studies involving 917 participants found that while nutritional supplementation during pulmonary rehabilitation could improve weight or selected outcomes, most studies failed to show a consistent, additional exercise-capacity benefit. The review also highlighted massive variation in supplements and rehabilitation protocols across different patient groups. Consequently, buyers cannot treat all products as interchangeable or assume that every patient will gain the exact same functional benefit. Programs must rigorously assess individual nutrition status and tolerance before standardizing repeat purchasing.[11]

The clearest opportunity lies in reducing the physical consumption burden while still supporting vital protein and energy targets between rehabilitation encounters. Medtrition introduced a 2-ounce protein cup in 2025, while Meiji documented 100 ml products delivering 200 kcal. Nutricia Respifor utilizes a 125 ml format specifically for COPD-related malnutrition. These examples perfectly illustrate how suppliers can compete on smaller serving sizes rather than simply adding bulk calories. Furthermore, home-based and telerehabilitation models drastically increase the value of shelf-stable, easy-to-administer formats because patients desperately need products that remain practical when the clinical team is not physically present.[15][17][18]

Which country CAGRs are profiled in the pulmonary rehabilitation nutrition market?

The following country CAGRs cover the 2026 to 2036 forecast period.

Table 2: Country CAGRs for the Pulmonary Rehabilitation Nutrition Market (CAGR, %), 2026 to 2036

Country	CAGR
South Korea	9.3%
UK	8.4%
USA	8.1%
Germany	7.8%
Japan	7.0%

Country-wise Analysis

• South Korea: South Korea records the highest profiled CAGR at 9.3% from 2026 to 2036. The Korea Disease Control and Prevention Agency updated its COPD information in June 2026, stating that roughly 13% of adults aged 40 and older have COPD, with diagnosis and treatment rates remaining concerningly low. Reimbursement can actively translate that disease burden into rehabilitation demand: a national HIRA analysis found that pulmonary rehabilitation use rose significantly after insurance coverage began in 2017. However, the same study found that roughly 70% of patients were treated at tertiary hospitals. Suppliers therefore face a high-growth market characterized by clear institutional concentration and persistent access gaps outside major urban centers.[9][10]
• UK: The UK is profiled at an 8.4% CAGR from 2026 to 2036. NICE updated its COPD quality standard in September 2023, explicitly calling for eligible stable patients with exercise limitation to be referred to pulmonary rehabilitation. Crucially, the same standard describes diet advice and support as a mandatory part of the program according to individual need. This formal pathway gives ONS purchasing a highly defined clinical context. However, demand is not automatic, as supplementation still depends on individual nutritional assessment and tolerance. Suppliers that seamlessly fit into dietitian workflows and support continuity after the usual multi-week rehabilitation program are vastly better positioned than products sold merely as general wellness nutrition.[4][5]
• USA: In the USA, the market is profiled to expand at an 8.1% CAGR from 2026 to 2036. CDC data released in April 2026 found that COPD prevalence among adults aged 45 and older was 7.0% in 2024, rising to a stark 10.6% in nonmetropolitan areas. The American Thoracic Society also recommends offering eligible patients a choice between center-based pulmonary rehabilitation and telerehabilitation. These conditions create two distinct purchasing needs: institutionally specified medical nutrition for supervised programs, and highly practical home formats for geographically dispersed patients. Commercial success therefore depends on broad distribution reach, remote adherence support, and strict product fit with dietitian-led care rather than prevalence alone.[1][2]
• Germany: Germany carries a 7.8% CAGR from 2026 to 2036. The federal health portal describes pneumological rehabilitation as a vital part of the COPD disease-management program, noting that patients may utilize either outpatient or inpatient rehabilitation. The portal also explicitly lists dietary changes among helpful non-pharmaceutical measures. This supports a highly structured care environment where nutrition is naturally considered within the broader rehabilitation framework. The market opportunity is therefore less about creating basic awareness of rehabilitation and much more about earning deep clinical acceptance within established pathways. Suppliers must demonstrate clear medical-nutrition positioning and practical administration while navigating reimbursement and institutional purchasing.[6]
• Japan: Japan is profiled at a 7.0% CAGR from 2026 to 2036. The Japanese Respiratory Society's 2026 COPD guideline explicitly includes nutrition assessment and nutrition management alongside pulmonary rehabilitation within non-pharmacologic care. Furthermore, a Japanese clinical-trial registry entry updated on September 4, 2026, documented a feasibility study combining inspiratory-muscle training with targeted nutrition therapy in COPD patients. The study demonstrates active, ongoing interest in pairing rehabilitation with targeted intake. Commercial uptake is likely to remain highly evidence-sensitive, favoring products that can precisely fit measured nutritional deficits and accommodate small-volume consumption rather than broad, untargeted supplementation.[7][8]

Who are the notable companies in the pulmonary rehabilitation nutrition market?

Abbott (Pulmocare), Nestle Health Science (Nutren Pulmonary), Danone Nutricia (Respifor), Fresenius Kabi, Meiji Holdings, Medtrition, Victus, and B. Braun are the notable companies profiled in this market.

Competition cleanly separates into three practical positions. Abbott, Nestle Health Science, and Danone Nutricia document highly specific pulmonary formulas utilizing different macronutrient strategies. Fresenius Kabi, Meiji Holdings, and B. Braun compete heavily through high-energy, high-protein, or compact clinical nutrition that can easily fit malnutrition and rehabilitation needs without being exclusively pulmonary. Medtrition concentrates intensely on modular protein delivery and very small serving formats. Victus offers broader complete and specialized nutrition across U.S. and Latin American channels. This structure matters immensely because buyers may choose a disease-specific formula for selected COPD patients, but general high-protein or compact ONS might be strongly preferred when volume tolerance or pure muscle preservation is the overriding requirement.[13][14][15][16][17][18][19][20]

• Pulmonary-specific formula position: Abbott (Pulmocare), Nestle Health Science (Nutren Pulmonary), and Danone Nutricia (Respifor).[13][14][15]
• Broad clinical ONS and compact nutrition position: Fresenius Kabi, Meiji Holdings, and B. Braun.[16][17][20]
• Modular and broader specialized nutrition position: Medtrition and Victus, with protein and complete-nutrition portfolios.[18][19]

Competitive Benchmarking: Pulmonary Rehabilitation Nutrition Market

Table 3: Competitive Benchmarking for the Pulmonary Rehabilitation Nutrition Market

Company	Pulmonary-Specific Formula	Compact Energy / Protein Format	Clinical ONS Breadth	Geographic Reach
Abbott (Pulmocare)	High	Medium	High	Pulmocare documented in Singapore; broader Abbott medical-nutrition portfolio spans multiple markets.
Nestle Health Science (Nutren Pulmonary)	High	Medium	High	Nutren Pulmonary documented in Middle East channels; broader Nestle Health Science presence is multinational.
Danone Nutricia (Respifor)	High	High	High	Nutricia product network plus documented medical-nutrition activity in Europe, USA, and China.
Fresenius Kabi	Medium	High	High	Fresubin portfolio documented across Europe, MENA, and other Fresenius Kabi markets.
Meiji Holdings	Not specified	High	Medium	Japan-centered clinical nutrition with selected Asian activity documented by Meiji.
Medtrition	Not specified	High	Medium	United States base; company states use in more than 50 countries.
Victus	Not specified	Not specified	Medium	United States and Latin American product channels are documented.
B. Braun	Not specified	Medium	High	Global B. Braun network; product availability varies by country.

Scoring basis: Pulmonary-Specific Formula measures whether a named product is explicitly formulated for COPD or chronic pulmonary disease. Compact Energy / Protein Format measures documented ability to deliver meaningful energy or protein in a reduced serving volume. Clinical ONS Breadth measures the range of medically supervised oral or sip-feed formats relevant to malnutrition and rehabilitation. High indicates broad or deep documented capability, while Medium indicates credible but narrower capability.

Key Developments in the Pulmonary Rehabilitation Nutrition Market

• In March 2025, Medtrition launched the ProSource Cup portfolio. The standard cup provides 20 g of complete protein in a highly concentrated 2-ounce serving, designed specifically for oral or enteral administration. This low-volume format is directly relevant to rehabilitation patients who struggle with meal volume or need concentrated protein between exercise sessions.[18]
• In March 2025, Meiji Holdings launched the Mei Balance Gyutto Soft Jelly series in Japan. Meiji reports that the product supplies 200 kcal in just 100 ml. This launch significantly expands the range of compact nutrition formats available to support patients who need meaningful energy in a very small serving during recovery.[17]
• In July 2025, Danone completed the acquisition of a majority stake in Kate Farms, combining it with its North American medical-nutrition platform. Danone stated the portfolio would improve access across hospitals and home settings, citing online and retail channels. While broader than pulmonary-specific products, the transaction vastly strengthens route-to-market capacity for specialized nutrition.[22]

Key Players in the Pulmonary Rehabilitation Nutrition Market

• Pulmonary-Specific Respiratory Nutrition
  • Abbott (Pulmocare)
  • Nestle Health Science (Nutren Pulmonary)
  • Danone Nutricia (Respifor)
• High-Energy and High-Protein Clinical ONS
  • Fresenius Kabi
  • Meiji Holdings
  • B. Braun
• Modular and Broader Specialized Nutrition
  • Medtrition
  • Victus

Pulmonary Rehabilitation Nutrition Market - Report Scope

Table 4: Report scope for the Pulmonary Rehabilitation Nutrition Market (USD Million), 2026 to 2036

Coverage field	Report scope
Market breakdown	Product Type; Condition; Program Setting; End User; Sales Channel
Quantitative Units	USD Million
Market Definition	Revenue from medically supervised pulmonary rehabilitation nutrition sold within the stated segmentation universe. It includes pulmonary-specific oral nutrition, high-protein rehabilitation formulas, and compact energy-dense ONS when sold for pulmonary rehabilitation use. It excludes pulmonary rehabilitation service fees, respiratory drugs and devices, tube-feed-only revenue outside this use case, general wellness supplements, and adjacent disease-specific nutrition.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	USA; UK; Germany; Japan; South Korea
Key Companies Profiled	Abbott (Pulmocare); Nestle Health Science (Nutren Pulmonary); Danone Nutricia (Respifor); Fresenius Kabi; Meiji Holdings; Medtrition; Victus; B. Braun
Forecast Period	2026 to 2036
Approach	Primary and secondary research with market triangulation.

Pulmonary Rehabilitation Nutrition Market - Research Methodology

Table 5: Research methodology for the Pulmonary Rehabilitation Nutrition Market (USD Million), 2026 to 2036

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams and subject-matter experts. Interviews examined purchasing decisions, product evaluation, adoption barriers, approval requirements, pricing considerations and expectations for technical support.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings and official corporate announcements. Claims relating to performance, applications, approvals and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation and country-level demand conditions. Forecast assumptions considered economic activity, regulatory developments, technology adoption and purchasing cycles.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns and findings from primary interviews. Adjacent categories, unsupported claims and overlapping revenues were excluded to reduce double counting and maintain consistency.

Pulmonary Rehabilitation Nutrition Market by Segments

Pulmonary Rehabilitation Nutrition Market segmented by Product Type:

• High-Fat Low-CHO Pulmonary ONS
• High-Protein Rehab Formulas
• Compact Energy-Dense ONS (Dyspnea-Adapted)
• Others

Pulmonary Rehabilitation Nutrition Market segmented by Condition:

• COPD
• Post-Pneumonia & ARDS Recovery
• Interstitial Lung Disease
• Others

Pulmonary Rehabilitation Nutrition Market segmented by Program Setting:

• Outpatient Pulmonary Rehab
• Inpatient Rehab
• Home-Based Programs

Pulmonary Rehabilitation Nutrition Market segmented by End User:

• Rehab Centers
• Homecare
• Hospitals
• Others

Pulmonary Rehabilitation Nutrition Market segmented by Sales Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online
• Institutional Tender
• Others

Pulmonary Rehabilitation Nutrition Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] American Thoracic Society (2023, August 15). Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline.
• [2] National Center for Health Statistics (2026, April 15). Prevalence of Selected Chronic Conditions Among Adults Age 45 and Older, by Age and Urbanization Level: United States, 2024. https://www.cdc.gov/nchs/products/databriefs/db557.htm
• [3] National Center for Health Statistics (2025, May 22). Chronic Obstructive Pulmonary Disease in Adults Age 18 and Older: United States, 2023.
• [4] NICE (2023, September 19). Quality statement 4: Pulmonary rehabilitation for stable COPD and exercise limitation.
• [5] NHS England (n.d.). Pulmonary rehabilitation.
• [6] Federal Ministry of Health, Germany (2023, March 17). Chronic obstructive pulmonary disease (COPD).
• [7] Japanese Respiratory Society (2026). COPD Diagnosis and Treatment Guideline 2026, 7th Edition.
• [8] Ministry of Health, Labour and Welfare, Japan (2026, September 4). Effect of inspiratory muscle training and nutritional intervention in patients with chronic obstructive pulmonary disease: Randomized feasibility trial.
• [9] Korea Disease Control and Prevention Agency (2026, June 1). Chronic Obstructive Pulmonary Disease.
• [10] Kim et al. (2022, October 14). Current status and trends of pulmonary rehabilitation in South Korea: National level data analysis using HIRA database from 2016 to 2018.
• [11] Aldhahir et al. (2020, February 13). Nutritional supplementation during pulmonary rehabilitation in COPD: A systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC7019390/
• [12] Cai et al. (2003, March). Effect of supplementing a high-fat, low-carbohydrate enteral formula in COPD patients.
• [13] Abbott (n.d.). Pulmocare.
• [14] Nestle Health Science (n.d.). NUTREN Pulmonary Vanilla.
• [15] Nutricia (n.d.). Respifor.
• [16] Fresenius Kabi (n.d.). Fresubin 2 kcal / 2 kcal FIBRE Drink.
• [17] Meiji Holdings Co., Ltd. (2025, June 26). Annual Securities Report for the Fiscal Year Ended March 31, 2025.
• [18] Medtrition, Inc. (2025, March 25). Medtrition, Inc. Launches the ProSource Cup Portfolio. https://www.medtrition.com/wp-content/uploads/2025/03/ProSource-Cup-Press-Release-March-2025.pdf
• [19] Victus (n.d.). Enterex Total.
• [20] B. Braun (n.d.). Sip Feeds.
• [21] B. Braun (2026, June 3). Nutricomp Soup.
• [22] Danone (2025, July 1). Danone completes the acquisition of Kate Farms, enhancing its U.S. specialized nutrition offerings. https://www.danone.com/newsroom/press-releases/kate-farms-acquisition.html
• [23] Danone (2024, May 1). Danone acquires Functional Formularies.
• [24] Danone (2023, November 6). Danone enters new adult medical nutrition category in China.
• [25] Danone (2023, September 13). Danone reinforces European medical nutrition manufacturing footprint with EUR 50 million line expansion in Poland.
• [26] Fresenius Kabi (2024, September 26). Advancing Medical Nutrition: Fresenius Kabi at ESPEN 2024.

This Report Answers

• How large is the Pulmonary Rehabilitation Nutrition Market in 2026, and what value is forecast for 2036?
• Which clinical and operating pressures support demand for pulmonary rehabilitation nutrition?
• Why does High-Fat Low-CHO Pulmonary ONS lead the Product Type category?
• Why does COPD lead the Condition category?
• How do the profiled country growth rates differ across South Korea, UK, USA, Germany, and Japan?
• Which profiled companies supply pulmonary-specific, compact, high-protein, or broader clinical nutrition formats?
• What limits adoption, repeat use, or switching between pulmonary rehabilitation nutrition products?
• What should rehabilitation teams and procurement buyers evaluate before purchasing or standardizing a product?